Duncker Streett & Co’s BioCryst Pharmaceuticals BCRX Stock Holding History

Duncker Streett & Co’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-500	Closed	-$3.52K	–	491
2023 Q2	$3.52K	Hold	500	–	–	﹤0.01%	447
2023 Q1	$4.17K	Hold	500	–	–	﹤0.01%	429
2022 Q4	$5.74K	Hold	500	–	–	﹤0.01%	432
2022 Q3	$6K	Hold	500	–	–	﹤0.01%	414
2022 Q2	$5K	Buy	+500	New	+$5.16K	﹤0.01%	425

Other funds holding BCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RP Management New York $139M AUM 37.98% 1-Year Est. Return

Duncker Streett & Co's BCRX Position: Q3 2023 in Review

Duncker Streett & Co sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2023, closing a stake of 500 shares — an estimated $3.52K sold.

Duncker Streett & Co first reported a position in BCRX in Q2 2022 and held it in 5 quarters. The position peaked at $6K in Q3 2022. 233 funds tracked by Wall St. Rank hold BCRX as of Q3 2023.

Duncker Streett & Co reported no remaining BioCryst Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
Duncker Streett & Co sold 500 BioCryst Pharmaceuticals shares in Q3 2023, an estimated $3.52K.
Duncker Streett & Co first reported a position in BioCryst Pharmaceuticals in Q2 2022 and held it in 5 quarters.
Duncker Streett & Co's BioCryst Pharmaceuticals position peaked at $6K in Q3 2022.
233 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2023.

Based on Duncker Streett & Co's 13F filing for Q3 2023, filed 26 Oct 2023.